2020 VC Landscape: Reviewing The First Six Months

Despite Global Disruption Due To COVID-19, Biopharma And Medtech Investors Remain Active

13 Jul 2020

• By Lucie Ellis-Taitt, Mandy Jackson, and Catherine Longworth

A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.

In the first half of 2020, biopharmaceutical companies completed around 130 private financings worth more than $1m individually, according to data from Biomedtracker (see Exhibit 1). Collectively, biopharma companies have raised around $7.5bn so far this year. The sector has also seen a number of “mega-rounds” in 2020, with several companies securing more than $150m in venture capital financing.

Open Media